Skip to content

Trial Summary

A Phase 1, Open-Label, Dose Escalation Study of ADG116 in Patients with Advanced/Metastatic Solid Tumors



ACTRN/NCT /ethics:


Scientific title:

Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors

Sponsor / Cooperative group:

Adagene Inc

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2020-01-06
Anticipated End Date2021-09-23

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Phone08 8292 2240
Principal InvestigatorDr Francis Parnis
Recruitment StatusRecruiting